ClinicalTrials.gg
Active, not recruitingNCT07172516X-CEEDUpdated Oct 13, 2026

A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

A Phase 3 interventional study of Azetukalner and Placebo in Bipolar Disorder, Bipolar Depression and Bipolar I Disorder, sponsored by Xenon Pharmaceuticals Inc.. Active, not recruiting at 44 sites in 4 countries. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Xenon Pharmaceuticals Inc. · Phase 3, Interventional, and Treatment

Updated Oct 13, 2026Now Active, not recruitingGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 837 studies in Bipolar Disorder with a site in United States — 77 open to participants now, 96 under way, 8 of them phase 3. Bipolar Disorder · United States.

Planned enrollment
52nd of 704
400 · median 58
Started
2025
with 24 others
Phase 3
117 of 837
3 open now
Primary completion
2028-06
later than 64 of 94 live
Registered
818th of 837
by date

Among the 837 studies in Bipolar Disorder with a site in United States, this one is the 52nd largest by planned enrollment of the 704 interventional ones that give a count, is one of 25 that started in 2025, is one of 117 in phase 3, reaches primary completion later than 64 of the 94 other live ones, and was the 818th registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

77 of the 837 studies in Bipolar Disorder with a site in United States are open now. Recruiting first, the newest first:

72 more — sign in →

All 77 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 837 studies in Bipolar Disorder with a site in United States, or all of them as a file.
02

Study summary

X-CEED is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of azetukalner in adult participants diagnosed with bipolar I or II disorder who are currently in a depressive episode (bipolar depression).

03

Conditions studied

  • Bipolar Disorder
  • Bipolar Depression
  • Bipolar I Disorder
  • Bipolar II Disorder

Browse trials for

Keywords

  • Bipolar
  • XEN1101
  • Azetukalner
04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Adults ≥18 and ≤74 years of age who experienced their first major depressive episode (MDE) prior to 50 years of age.
  • (BMI) ≥18 kg/m2 and ≤40 kg/m2.
  • Meets the , Fifth Edition, Text Revision (DSM-5-TR) criteria for bipolar I or II disorder and is currently in a MDE, confirmed using the Mini International Neuropsychiatric Interview (MINI).
  • Current MDE must has a duration of ≥4 weeks and ≤12 months.

Key Exclusion Criteria:

  • Participant has any type of major depressive disorder (MDD) diagnosis, including MDD with psychotic features, MDD with catatonia, MDD with seasonal pattern, or postpartum depression.
  • Participant has any nonbipolar psychiatric diagnosis.
  • Participant has a substance use disorder (excluding tobacco) within the 6 months prior to screening visit.
  • Participant has a symptomatic eating disorder within the 12 months prior to screening visit.
  • Participant has a Young Mania Rating Scale (YMRS) score >12 points at screening visit or randomization.
  • Participant has been hospitalized for mania within the 30 days prior to screening visit.
  • Participant is considered treatment-resistant in the current bipolar depressive episode, defined as having treatment resistance (no remission) to ≥2 different medications approved by the regional regulatory authority at an adequate dose (per regulatory approved label) and for an adequate duration (at least 6 weeks).
  • Participant has had an active suicidal plan/intent within the 6 months prior to screening, presence of suicidal behavior in the last 12 months.
  • Participant has self-injurious behavior without intent to die in the 12 months prior to screening.
  • Participant has used antidepressants, mood stabilizers, anticonvulsants, antipsychotics, or other prohibited medications within the 1 week or within a period less than 5 times the drug's half-life, whichever is longer prior to randomization.
  • Participants with medical conditions that may interfere with the purpose or conduct of the study.
  • Participant is pregnant, breastfeeding, or planning to become pregnant.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Azetukalner

    Azetukalner 20 mg

    Drug: Azetukalner

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

  • Azetukalner 20 mg taken orally once a day with food (with the evening meal when possible) for 6 weeks

    Also known as: XEN1101

  • DrugPlacebo

    Placebo taken orally once a day with food (with the evening meal when possible) for 6 weeks

06

What researchers measure

Primary outcomes

  1. Change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 6.

    Time frame: Baseline to Week 6

Secondary outcomes

  1. Change from baseline in the Clinical Global Impression of Severity (CGI-S) score at Week 6.

    Time frame: Baseline to Week 6

  2. Change from baseline in the MADRS total score at Week 1.

    Time frame: Baseline to Week 1

  3. Change from baseline in the Snaith-Hamilton Pleasure Scale (SHAPS) total score at Week 6.

    Time frame: Baseline to Week 6

07

Study locations

44 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jun 2028, 34 months after the start.

Of 29 industry-sponsored phase 3 interventional studies under Bipolar Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 49. This study's planned 34 months is close to that.

Counting every sponsor, half of 43 studies reached it within 37 months; a quarter within 21 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2025
First posted
Sep 15, 2025
StartActual
Aug 8, 2025
Primary completionEst.
Jun 2028
CompletionEst.
Aug 2028
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Recruiting→Active, not recruiting
    + 2 other changes: contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07172516
Responsible party
Sponsor
First posted
Sep 15, 2025
Start date
Aug 8, 2025
Primary completion
Jun 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Oct 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: XEN1101

Start the discussion